FibroGen's Lead Drug Fails Again, Stock Crashes.
TL;DR Summary
FibroGen's pamrevlumab failed in a Phase III study for idiopathic pulmonary fibrosis, marking the company's third late-stage miss in two months. The drug was not better than placebo at a lung function test and did not delay disease progression. However, it was generally safe and well-tolerated.
Topics:business#clinical-trials#fibrogen#healthcare#idiopathic-pulmonary-fibrosis#pamrevlumab#phase-iii
- FibroGen reports third PhIII failure in two months, this time in idiopathic pulmonary fibrosis Endpoints News
- FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis Yahoo Finance
- Analyst Downgrades FibroGen On Questions Regarding Future Direction - FibroGen (NASDAQ:FGEN) Benzinga
- FibroGen Tanks after Phase 3 Data in Pulmonary Fibrosis Disappoints TipRanks
- FGEN Stock Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug Investor's Business Daily
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
67%
138 → 46 words
Want the full story? Read the original article
Read on Endpoints News